Nanoparticle based drug delivery system for triple negative Breast Cancer treatment
TMP Universal Journal of Advances in Pharmaceutical Sciences · 08.03.2026 · 2 (1)
DOI: 10.69557/52ts5r95 ↗Kurz gefasst
Fachartikel in der Zeitschrift TMP Universal Journal of Advances in Pharmaceutical Sciences, online erschienen am 08.03.2026. Verfasst von Arpita krushnat Jadhav.
Abstract (Originalsprache)
Triple negative Breast cancer is an aggressive and fast growing sub- type of breast cancer that lack of estrogen,progesterone and HER2 receptor. Because it misses these receptors, hormone therapies and HER2-targeted drugs are ineffective. Conventional chemotherapy often fails due to drug resistance, tumor recurrence and the presence of stem cell, which possess self-renewal and tumor-initiating capabilities. Currently, there are no approved targeted therapies for Triple Negative Breast Cancer. However, intense research is ongoing to identify specific targets and develop additional and better systemic treatment options.Recent advances in nanomedicine have introduced dual-targeted stimuli-responsive nanoparticles as promising therapeutic platforms capable of selectively targeting Cancer Stem Cells while responding to the tumor microenvironment.This review display the nanoparticle-based targeting strategies, stimuli-responsive mechanisms, and recent progress in dual-targeted nano systems for effective TNBC therapy.
Zitieren
APA
Jadhav, A. K. (2026). Nanoparticle based drug delivery system for triple negative Breast Cancer treatment. TMP Universal Journal of Advances in Pharmaceutical Sciences, 2(1). https://doi.org/10.69557/52ts5r95
Vancouver
Jadhav AK. Nanoparticle based drug delivery system for triple negative Breast Cancer treatment. TMP Universal Journal of Advances in Pharmaceutical Sciences. 2026;2(1). doi:10.69557/52ts5r95
BibTeX
@article{Jadhav2026,
author = {Jadhav, Arpita krushnat},
title = {Nanoparticle based drug delivery system for triple negative Breast Cancer treatment},
journal = {TMP Universal Journal of Advances in Pharmaceutical Sciences},
year = {2026},
volume = {2},
number = {1},
doi = {10.69557/52ts5r95}
}
EUVIMED